Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

Immatics N.V.: Vestal Point Capital, LP discloses a stake of more than 5% (Schedule 13G)

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Vestal Point Capital, LP disclosed a stake of more than 5% in Immatics N.V. via a Schedule 13G filing with the SEC (accession 0000902664-26-004576). The exact share count and percentage were not specified in the headline disclosure. The filing signals that Vestal Point has crossed the 5% passive-investor threshold in the clinical-stage biotech. Investors will watch for further detail on the position size and any subsequent 13G amendments.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Vestal Point Capital, LP, Immatics N.V.